Lantern Pharma Reports Positive Phase 1a Data For LP-184 In Advanced Solid Tumors
(RTTNews) - Lantern Pharma Inc. (LTRN), a clinical-stage biotechnology company, on Wednesday shared additional details and clinical insights from its completed Phase 1a dose-escalation study of LP-184.
The trial showed encouraging, durable disease control in heavily pre-treated patients with advanced solid tumors, many of whom had DNA damage repair (DDR) pathway deficiencies. The study met all primary endpoints for safety and tolerability.
Lantern said it plans to advance LP-184 into multiple Phase 1b/2 trials.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.